SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following positive regulatory advancements for its ANKTIVA therapy, with the FDA outlining a path to resubmission for papillary bladder cancer that requires no new clinical trials. This news, combined with recent international approvals, is fueling strong community sentiment around the potential for a "cancer cure" and intense discussions anticipating a substantial short squeeze.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a non-exclusive license agreement with Pfizer for its Matrix-M adjuvant, providing significant validation for the technology. This deal, building on previous collaborations, is driving community excitement and fueling discussions about the adjuvant's potential applications and the company's future partnerships amidst notable short interest.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to heightened geopolitical tensions, specifically former President Trump's recent tariff threats against NATO allies over Greenland and an anticipated Supreme Court ruling on presidential tariff authority. This has sparked a fierce debate among investors, with some advocating to "buy the dip" and anticipating a rapid "Taco Trade" rebound, while others warn of a significant market correction. Adding to the volatility are concerns surrounding Japan's bond market instability, creating a complex and uncertain trading environment.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as former President Trump's renewed threats of tariffs on NATO allies, particularly over the acquisition of Greenland, spark fears of a trade war with Europe. This escalating geopolitical tension is causing widespread market jitters and calls for caution, though many investors are also discussing it as a potential "buy the dip" opportunity for growth stocks.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point among investors, primarily driven by its upcoming earnings report and the proposed all-cash acquisition of Warner Bros. Discovery assets, which has sparked a debate over potential growth versus debt concerns. The community is closely watching for strong ad-tier performance and subscriber metrics, particularly after a previous tax-related earnings miss, with sentiment split on whether recent oversold conditions signal a significant rebound or continued volatility.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is trending strongly as renewed geopolitical tensions, including recent tariff threats concerning European countries over Greenland, fuel a broad flight to safety. The community views gold as a crucial hedge against eroding fiat currency confidence and economic instability, driving prices to consistent new highs. Many are discussing significant further appreciation as these global uncertainties persist.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin ($APP) is experiencing significant volatility and a notable price decline following a new short report alleging the company's involvement in money laundering. This report has sparked intense debate among investors, with many attributing the drop to market manipulation and viewing it as a buying opportunity, while others express concern over the serious accusations despite recent bullish analyst upgrades.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid intense debate surrounding the Federal Reserve's independence, fueled by a federal probe into its Chair and the administration's aggressive policy maneuvers impacting bond markets. Investors are actively discussing whether long-term treasuries offer a crucial hedge against a potential economic slowdown or face further headwinds from escalating national debt and geopolitical uncertainty.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, with community discussions highlighting its strong efficacy in treatment-resistant patients. Investors are actively debating the potential for this novel oral ITK inhibitor to disrupt the significant atopic dermatitis market, fueling speculation of future partnerships or an acquisition and validating its broader immune-modulating platform.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx ($ARDX) is trending amid widespread speculation following reports that Zydus Lifesciences is in talks to acquire a controlling stake or key assets, with the community actively discussing the potential for a significant buyout. This buzz is amplified by the recent extension of patents for IBSRELA and XPHOZAH until 2041 and bullish revenue projections, fundamentally altering valuation perspectives and putting pressure on short positions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tim Kutzkey Purchases 12,470 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) Director Tim Kutzkey bought 12,470 shares of Surrozen stock in a transaction that occurred on Tuesday, January 13th. The stock was bought at an average...

Surrozen (NASDAQ:SRZN) Major Shareholder Buys $110,404.77 in Stock

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 5,523 shares of the stock in a transaction dated Wednesday, January 14th. The shares were bought at an...

Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 5,523 Shares

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) Director Tim Kutzkey acquired 5,523 shares of the firm's stock in a transaction that occurred on Wednesday, January 14th. The shares were purchased at...

Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 12,470 Shares

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) Director Tim Kutzkey purchased 12,470 shares of the business's stock in a transaction on Tuesday, January 13th. The shares were bought at an average...

Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Buys 12,470 Shares

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) major shareholder Group Gp Lp Column III purchased 12,470 shares of the firm's stock in a transaction dated Tuesday, January 13th. The shares were...

Yang Li Sells 1,118 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) VP Yang Li sold 1,118 shares of the company's stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $19.87, for...

Insider Selling: Surrozen (NASDAQ:SRZN) COO Sells 1,566 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) COO Charles Williams sold 1,566 shares of the company's stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average...

Surrozen, Inc. (NASDAQ:SRZN) Sees Significant Growth in Short Interest

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 197,047 shares...

Braidwell LP Buys Shares of 140,000 Surrozen, Inc. $SRZN

Braidwell LP purchased a new position in shares of Surrozen, Inc. (NASDAQ:SRZN - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The...

Stempoint Capital LP Acquires 445,713 Shares of Surrozen, Inc. $SRZN

Stempoint Capital LP increased its stake in Surrozen, Inc. (NASDAQ:SRZN - Free Report) by 185.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission...

Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

SRZN
Surrozen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRZN News

SRZNSurrozen Inc